NASDAQ:PNT POINT Biopharma Global (PNT) Stock Forecast, Price & News $6.68 +0.01 (+0.15%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$6.57▼$6.8650-Day Range$6.67▼$9.1052-Week Range$5.59▼$11.13Volume604,881 shsAverage Volume620,135 shsMarket Capitalization$707.07 millionP/E Ratio7.68Dividend YieldN/APrice Target$14.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media POINT Biopharma Global MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside114.4% Upside$14.33 Price TargetShort InterestBearish8.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector307th out of 969 stocksPharmaceutical Preparations Industry123rd out of 452 stocks 3.5 Analyst's Opinion Consensus RatingPOINT Biopharma Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, POINT Biopharma Global has a forecasted upside of 114.4% from its current price of $6.69.Amount of Analyst CoveragePOINT Biopharma Global has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.17% of the float of POINT Biopharma Global has been sold short.Short Interest Ratio / Days to CoverPOINT Biopharma Global has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in POINT Biopharma Global has recently decreased by 0.14%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPOINT Biopharma Global does not currently pay a dividend.Dividend GrowthPOINT Biopharma Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PNT. Previous Next 4.0 News and Social Media Coverage News SentimentPOINT Biopharma Global has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for POINT Biopharma Global this week, compared to 1 article on an average week.Search Interest5 people have searched for PNT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added POINT Biopharma Global to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.53% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for POINT Biopharma Global are expected to grow in the coming year, from ($1.00) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of POINT Biopharma Global is 7.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.64.Price to Earnings Ratio vs. SectorThe P/E ratio of POINT Biopharma Global is 7.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.66.Price to Book Value per Share RatioPOINT Biopharma Global has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About POINT Biopharma Global (NASDAQ:PNT) StockPOINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More PNT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PNT Stock News HeadlinesSeptember 30, 2023 | finance.yahoo.comWill Weakness in POINT Biopharma Global Inc.'s (NASDAQ:PNT) Stock Prove Temporary Given Strong Fundamentals?September 29, 2023 | markets.businessinsider.comPoint Biopharma Global: Promising Phase III Data and Potential Market Share CaptureOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 27, 2023 | markets.businessinsider.comEQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT BiopharmaSeptember 18, 2023 | finance.yahoo.comPOINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted RadioligandsAugust 20, 2023 | finance.yahoo.comPOINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Are More Bearish Than They Used To BeAugust 14, 2023 | finance.yahoo.comPOINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAugust 2, 2023 | seekingalpha.comPOINT Biopharma: Leading The Future Of Radioligand TherapyOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 1, 2023 | finance.yahoo.comWith 50% institutional ownership, POINT Biopharma Global Inc. (NASDAQ:PNT) is a favorite amongst the big gunsAugust 1, 2023 | seekingalpha.comPOINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 TrialsJuly 31, 2023 | finance.yahoo.comITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177July 15, 2023 | fool.comPoint Biopharma Global (NASDAQ: PNT)June 26, 2023 | finance.yahoo.comPOINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual CongressJune 26, 2023 | finance.yahoo.comPOINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled RadioligandsJune 22, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Buy Rating for POINT Biopharma Global (PNT)June 12, 2023 | finance.yahoo.comPOINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of DirectorsJune 7, 2023 | finance.yahoo.comPOINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023May 25, 2023 | finance.yahoo.comPOINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCOMay 19, 2023 | seekingalpha.comPOINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong FinancialsMay 17, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: POINT Biopharma Global (PNT), NewAmsterdam Pharma Company (NAMS)May 16, 2023 | msn.comOppenheimer Reiterates POINT Biopharma Global (PNT) Outperform RecommendationMay 15, 2023 | msn.comWhy Shares of Point Biopharma Global Rose MondayMay 15, 2023 | finance.yahoo.comPOINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 15, 2023 | finance.yahoo.comPOINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope ManufacturerMay 14, 2023 | investing.comPOINT Biopharma Global (PNT) Earnings Dates & ReportsMay 10, 2023 | finance.yahoo.comAre Investors Undervaluing POINT Biopharma Global Inc. (NASDAQ:PNT) By 46%?See More Headlines Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.33 High Stock Price Forecast$16.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+114.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.87 Trailing P/E Ratio7.68 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net MarginsN/A Pretax Margin52.79% Return on Equity22.69% Return on Assets19.86% Debt Debt-to-Equity Ratio0.01 Current Ratio10.51 Quick Ratio10.51 Sales & Book Value Annual Sales$226.58 million Price / Sales3.12 Cash Flow$0.94 per share Price / Cash Flow7.10 Book Value$4.68 per share Price / Book1.43Miscellaneous Outstanding Shares105,770,000Free Float88,843,000Market Cap$707.07 million OptionableNot Optionable Beta0.22 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Allan Charles Silber (Age 73)Exec. Chairman Comp: $1.02MDr. Joe A. McCann Ph.D. (Age 45)CEO & Director Comp: $1.06MDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $318.49kMs. Jessica D. Jensen M.P.H. (Age 42)MPH, Exec. VP of Clinical Devel. Comp: $816.17kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, CFO & Corp. Sec. Ms. Justyna Kelly M.Sc. (Age 38)Chief Operating Officer Ms. Jazz BraichSVP of People & CultureMr. Ari ShomairVP of Corp. Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Exec. VP of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Sr. VP of Bus. Devel.More ExecutivesKey CompetitorsCassava SciencesNASDAQ:SAVAArcturus TherapeuticsNASDAQ:ARCTVera TherapeuticsNASDAQ:VERANewAmsterdam PharmaNASDAQ:NAMSCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsBarclays PLCBought 14,269 shares on 9/21/2023Ownership: 0.109%Yarbrough Capital LLCBought 42,130 shares on 8/25/2023Ownership: 0.040%Perceptive Advisors LLCBought 500,000 shares on 8/24/2023Ownership: 0.000%California State Teachers Retirement SystemSold 2,064 shares on 8/21/2023Ownership: 0.081%Orion Portfolio Solutions LLCBought 15,061 shares on 8/17/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions PNT Stock - Frequently Asked Questions Should I buy or sell POINT Biopharma Global stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PNT shares. View PNT analyst ratings or view top-rated stocks. What is POINT Biopharma Global's stock price forecast for 2023? 5 Wall Street research analysts have issued twelve-month price objectives for POINT Biopharma Global's stock. Their PNT share price forecasts range from $13.00 to $16.00. On average, they expect the company's stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 114.4% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts. How have PNT shares performed in 2023? POINT Biopharma Global's stock was trading at $7.29 at the beginning of 2023. Since then, PNT stock has decreased by 8.3% and is now trading at $6.6850. View the best growth stocks for 2023 here. When is POINT Biopharma Global's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our PNT earnings forecast. How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.05. The firm had revenue of $4.87 million for the quarter, compared to analyst estimates of $8.50 million. What is POINT Biopharma Global's stock symbol? POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT." How do I buy shares of POINT Biopharma Global? Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is POINT Biopharma Global's stock price today? One share of PNT stock can currently be purchased for approximately $6.69. How much money does POINT Biopharma Global make? POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $707.07 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.87 on an earnings per share basis. How many employees does POINT Biopharma Global have? The company employs 129 workers across the globe. How can I contact POINT Biopharma Global? POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417. This page (NASDAQ:PNT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.